menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Navigating CLL Treatment: A Deep Dive into Efficacy and Safety

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    The therapeutic landscape for chronic lymphocytic leukemia (CLL) has significantly evolved over the last decade, with BTK inhibitors and a BCL-2 inhibitor being the two mainstays of treatment. But before selecting a therapeutic approach, it’s important to consider a treatment’s efficacy and safety profile along with the disease characteristics, patient characteristics, and patient preferences. That’s why Dr. Seema Bhat joins Dr. John Russell to examine the efficacy and safety of available CLL treatment options and how we can balance the potential benefits with the possible side effects. Dr. Bhat is an Associate Professor in the Department of Internal Medicine in the Division of Hematology at Ohio State University.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    The therapeutic landscape for chronic lymphocytic leukemia (CLL) has significantly evolved over the last decade, with BTK inhibitors and a BCL-2 inhibitor being the two mainstays of treatment. But before selecting a therapeutic approach, it’s important to consider a treatment’s efficacy and safety profile along with the disease characteristics, patient characteristics, and patient preferences. That’s why Dr. Seema Bhat joins Dr. John Russell to examine the efficacy and safety of available CLL treatment options and how we can balance the potential benefits with the possible side effects. Dr. Bhat is an Associate Professor in the Department of Internal Medicine in the Division of Hematology at Ohio State University.

Facebook Comments

Schedule26 May 2024